Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of Nova Scotia — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Bank of Nova Scotia trades at $87.45 (market cap $107.21B). The key difference: Bank of Nova Scotia is far larger — about 129.8× Amphastar Pharmaceuticals Inc's market cap, and Bank of Nova Scotia pays a 3.67% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BNS | |
|---|---|---|
Market Cap | $826.08M | $107.21B |
Sector | Health | Financials |
52-Week High | $30.81 | $87.59 |
52-Week Low | $16.87 | $54.50 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BNS trades at $87.59, up 1.78% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.47, exceeding expectations, and maintains a net income margin of 24.86%. Recent news highlights dividend strength and the acquisition of MapleMark Bank to bolster growth. Analyst consensus is 53% buy, with a P/E of 17.15 indicating reasonable valuation.
Outlook is positive due to consistent earnings performance and strategic acquisitions, but risks include high debt levels and economic sensitivity. The stock offers income appeal with a $1.14 dividend, yet investors should monitor credit provisions amid soft economic conditions noted in Q2 2026 reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
